GSK Expands Share Buyback Program with Recent Share Purchase

GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.

GSK plc has announced the purchase of 218,000 of its own ordinary shares as part of its ongoing share buyback program. These shares, acquired at prices ranging from 1,830.00p to 1,848.00p, will be held as treasury shares. This transaction is part of a non-discretionary agreement with BNP Paribas SA, and since September 2025, GSK has repurchased a total of 11,764,733 ordinary shares. This move is significant as it affects the company’s capital structure and could influence shareholder value by reducing the number of shares available in the market, potentially increasing earnings per share.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s strong technical indicators and positive earnings call sentiment are the most significant factors driving the high score. The company’s solid financial performance, despite some concerns about cash flow and debt reliance, supports a favorable outlook. Valuation metrics further enhance its attractiveness, making GSK a compelling investment in the drug manufacturing sector.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company engaged in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company focuses on innovative solutions in the healthcare sector, aiming to improve the quality of human life by enabling people to do more, feel better, and live longer.

Average Trading Volume: 8,911,681

Technical Sentiment Signal: Buy

Current Market Cap: £73.44B

Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.